pharmaphorum2y
Dupixent falls short in phase 3 chronic spontaneous urticaria trial
CSU is a severe form of hives that affects around 1% of ... In CUPID STUDY B, IL-4 and IL-13 inhibitor Dupixent (dupilumab) wasn't able to achieve a significant improvement in symptoms in Xolair ...
pharmaphorum2y
Dupixent nears EU approval for rare skin disease prurigo nodularis
The EMA's human medicines committee (CHMP) has recommended IL-4 and IL-13 inhibitor Dupixent (dupilumab) to treat adults with moderate to severe PN, a disease which causes hard lumps to form on ...
FiercePharma8d
Regeneron tangles with Sanofi over commercial transparency in long-running Dupixent collaboration
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...
Business Insider15d
Regeneron: Strong Buy Rating Driven by Dupixent’s Growth and Promising Pipeline Developments
One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...